LPL Financial
GRCE

LPL Financial’s Grace Therapeutics GRCE Stock Holding History

LPL Financial’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-365
Closed -$10K – 4434
2021
Q2 		$10K Hold
365
– – ﹤0.01% 4214
2021
Q1 		$11K Hold
365
– – ﹤0.01% 4066
2020
Q4 		$6K Buy
+365
New +$4.22K ﹤0.01% 3803

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial's GRCE Position: Q3 2021 in Review

LPL Financial sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 365 shares — an estimated $10K sold.

LPL Financial first reported a position in GRCE in Q4 2020 and held it in 3 quarters. The position peaked at $11K in Q1 2021. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

  • LPL Financial reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
  • LPL Financial sold 365 Grace Therapeutics shares in Q3 2021, an estimated $10K.
  • LPL Financial first reported a position in Grace Therapeutics in Q4 2020 and held it in 3 quarters.
  • LPL Financial's Grace Therapeutics position peaked at $11K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on LPL Financial's 13F filing for Q3 2021, filed 15 Nov 2021.